XML 20 R7.htm IDEA: XBRL DOCUMENT v3.22.2
Condensed Statements of Cash Flows (Unaudited) - USD ($)
 9 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Operating activities    
Net loss $ (8,625,269) $ (7,305,005)
Adjustments to reconcile net loss to net cash used in operating activities:    
Amortization and depreciation 85,198 58,385
Stock-based compensation 691,336 1,451,040
Issuance costs attributed to financing activities 3,053
Revaluation of convertible notes (1,974)
Non-cash lease expense 80,020 41,056
Payroll protection program loan forgiveness   (83,333)
Change in assets and liabilities:    
Accounts receivable 48,336 (40,096)
Inventory (355,998) (52,182)
Prepaid and other assets (145,462) (45,620)
Accounts payable (87,197) (466,128)
Accrued expenses, deferred revenue, operating leases and other liabilities (228,315) (132,716)
Net cash used in operating activities (8,537,351) (6,573,520)
Investing activities    
Purchase of fixed assets (209,044) (31,970)
Net cash used in investing activities (209,044) (31,970)
Financing activities    
Issuance costs related to convertible notes (3,053)
Proceeds from issuance of common stock in connection with public offering and private placements 13,350,582 8,829,236
Proceeds from issuance of warrants in connection with private placement 3,670,764
Exercise of warrants 275,000
Exercise of stock options 10,146
Deferred offering costs (24,179)
Issuance costs related to public offering and private placements (1,327,300) (1,198,080)
Net cash provided by financing activities 12,023,282 11,559,834
Net increase in cash 3,276,887 4,954,344
Cash at beginning of period 6,901,346 4,036,397
Cash at end of period 10,178,233 8,990,741
Supplemental non-cash financing and investing transactions:    
Conversion of convertible notes into equity 1,005,232
Unpaid issuance costs and non-cash adjustments attributed to convertible notes and private placements 50,400
Reclass of deferred offering costs to additional paid-in capital in connection with public offering $ 24,980